Target intelligence / Profile preview

Major allergen Der f 1 (Der f 1)

Target
Der f 1
Molecular classification
Enzyme, Cysteine protease, Allergen, Peptidase C1 family
01

Overview

Major allergen Der f 1 is a 25 kDa cysteine protease produced by the American house dust mite, Dermatophagoides farinae (UniProt: P16311). It is primarily found in mite fecal pellets and serves a biological role in digesting skin cells shed by humans (PubMed: 22150126). In sensitized individuals, Der f 1 acts as a potent allergen that triggers Type I hypersensitivity, leading to conditions such as allergic asthma, rhinitis, and atopic dermatitis (NIH: 1.1.4). The protein's enzymatic activity contributes to its allergenicity by cleaving tight junction proteins in the respiratory and skin epithelia, which increases barrier permeability and facilitates immune system exposure (NIH: 1.2.1). Der f 1 is a key component in allergen-specific immunotherapy (AIT) drugs like Odactra and Acarizax, which are designed to induce immune tolerance (TGA: 1.3.1). These therapies work by promoting the development of regulatory T cells and shifting the antibody response from IgE to protective IgG4, thereby reducing the clinical symptoms of mite-related allergies (NIH: 1.2.4).

Other names
Dermatophagoides farinae allergen 1Der f IHouse dust mite allergen Der f 1Mite allergen Der f 1
02

Mechanism of action

Induction of immunological tolerance via allergen-specific immunotherapy (AIT), involving the expansion of regulatory T cells and the production of allergen-specific IgG4 blocking antibodies.

03

Biological functions

ProteolysisImmune responseEpithelial barrier disruption
04

Disease associations

InflammationOther
05

Safety considerations

AnaphylaxisSystemic allergic reactionsLocal application site reactions (e.g., oral pruritus, throat irritation)Eosinophilic esophagitis
06

Interacting drugs

Dermatophagoides farinae allergen extract

4 more in the full profile.

07

Biomarkers

Specific IgE (sIgE)Specific IgG4 (sIgG4)sIgG4/sIgE ratioIL-10TGF-beta

Beyond the preview

Go deeper on Major allergen Der f 1 (Der f 1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Major allergen Der f 1 (Der f 1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call